Thomas Klima
Chief Operating Officer chez BLUEBIRD BIO, INC.
Fortune : 159 795 $ au 31/03/2024
Postes actifs de Thomas Klima
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BLUEBIRD BIO, INC. | Chief Operating Officer | 08/08/2022 | - |
| Corporate Officer/Principal | 10/05/2021 | 08/08/2022 |
Historique de carrière de Thomas Klima
Anciens postes connus de Thomas Klima
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GAMIDA CELL LTD. | Corporate Officer/Principal | 07/01/2019 | 01/12/2020 |
| NAVIDEA BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 05/01/2015 | 08/03/2017 |
| DENDREON CORPORATION | Sales & Marketing | 01/09/2009 | 01/09/2012 |
Formation de Thomas Klima
| Western State College of Colorado | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Israël | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Sales & Marketing | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Health Technology |
| BLUEBIRD BIO, INC. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
- Bourse
- Insiders
- Thomas Klima
- Expérience
